Arca
Skip to content

Opioid use disorder

Drug research and approvals for opioid use disorder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 235 studies of opioid use disorder are recruiting on ClinicalTrials.gov, and Health Canada has authorized 10 drug trials for it since 2013.

  • Recruiting worldwide: 235
  • Trials authorized in Canada: 10
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 235 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Oct 1, 2026Bridge study: buprenorphine xr real-world induction, dosing, and gradual evaluationBUPRENORPHINEDR. NAVNEET SINGH KHOSAPending
May 29, 2026A single-site, single arm, pilot clinical trial at vancouver general hospital to evaluate the safety, feasibility and effectiveness of restarting individuals…METHADONEVANCOUVER COASTAL HEALTH UNIVERSITY OF BRITISH COLUMBIAPending
Dec 18, 2025A phase 2, randomized, double-blind, placebo-controlled study with a separate open-label cohort to evaluate the efficacy and safety of brenipatide as…BRENIPATIDE (LY3537031) / BUPRENORPHINE-NALOXONEEli LillyOngoing
Sep 24, 2025Symptom-inhibited naloxone induction (sini) for initiating buprenorphine/naloxone and buprenorphine extended release in opioid use disorder.NALOXONE / BUPRENORPHINE / NALOXONE-BUPRENORPHINEDR. POUYA AZAROngoing
Oct 6, 2023Open-label, single arm study of psilocybin-assisted therapy for opioid use disorder: a feasibility studyPSILOCYBIN (PEX010)FILAMENT HEALTH CORP.Pending
Jul 20, 2023Evaluating tetrahydrocannabinol as an adjunct to opioid agonist therapy for individuals living with opioid use disorder: a phase II, placebo-controlled,…CANNABIS (DELTA-9-TETRAHYDROCANNABINOL-CANNABIDIOL)BRITISH COLUMBIA CENTRE ON SUBSTANCE USEClosed
Mar 11, 2022A randomised, double blind study comparing 2 maintenance dosing regimens of buprenorphine extended release subcutaneous injection (rbp 6000) in treatment…BUPRENORPHINE (RBP-6000)IndiviorOngoing
Mar 12, 2021A pilot study using low dose buprenorphine patches for initiation of opioid withdrawal treatment in patients with opioid use disorder to improve successful…BUPRENORPHINEDR. DARREN R. CHRISTENSENPending
Feb 5, 2021Evaluating microdosing in the emergency department: a randomized clinical trial of buprenorphine/naloxone microdosing vs. standard dosing (emed study)BUPRENORPHINE-NALOXONEUNIVERSITY OF BRITISH COLUMBIAOngoing
Feb 4, 2020Comparing rapid micro-induction and induction of buprenorphine/naloxone for opioid use disorder based on the asam guidelines: a parallel group superiority…BUPRENORPHINE-NALOXONE/ HYDROMORPHONEVANCOUVER GENERAL HOSPITAL AND UNIVERSITY OF BRITISH COLUMBIA FOUNDATIONPending

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.